Making Pharma Personal

Paul Perreault, CEO and Managing Director of biotherapies company CSL Behring, often receives messages from people celebrating the great landmarks in their lives. There is nothing so very extraordinary about that – except these are from patients whom he has helped during his time in the business. “I wasn’t always an executive, so I started in the business, and I know patients and their families personally, across the country,” he begins. “At different levels of jobs that I’ve had in the organization, I’ve interacted with patients on a very direct and one-on-one level. And I was around when there were shortages of products for patients, and patients were getting sick, and some died. And I was trying to access products for these patients - even from competitors, because it was about taking care of the patients. And today, I get pictures and postcards of them, their graduations from high school, and weddings, and these sorts of things.” Personal stake All this means that, while Perreault obviously drives CSL Behring’s patient-centric strategy at the executive level, there is something deeper going on for him. “I have a personal stake in this,” he says simply, in an interview ahead of his presentation at eyeforpharma Philadelphia. The company is a global leader in plasma protein biotherapeutics, which are used to treat serious and rare conditions such as hemophilia and von Willebrand disease, immune deficiencies and genetic emphysema. “I tell people that ...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news